Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 15 results:
Author Title Type [ Year(Asc)]
Filters: Author is Evans, M.  [Clear All Filters]
2020
W. D. Strain, Tsang, C., Hurst, M., McEwan, P., Unadkat, M., Meadowcroft, S., Shardlow, R., and Evans, M., “What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient”, Diabetes Ther, vol. 11, pp. 1381-1395, 2020.
2019
C. Linde, Bakhai, A., Furuland, H., Evans, M., McEwan, P., Ayoubkhani, D., and Qin, L., “Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom”, J Am Heart Assoc, vol. 8, p. e012655, 2019.
C. Linde, Qin, L., Bakhai, A., Furuland, H., Evans, M., Ayoubkhani, D., Palaka, E., Bennett, H., and McEwan, P., “Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK”, ESC Heart Fail, 2019.
2018
H. Furuland, McEwan, P., Evans, M., Linde, C., Ayoubkhani, D., Bakhai, A., Palaka, E., Bennett, H., and Qin, L., “Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink”, BMC Nephrol, vol. 19, p. 211, 2018.
J. Gordon, McEwan, P., Idris, I., Evans, M., and Puelles, J., “Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study”, BMJ Open Diabetes Res Care, vol. 6, p. e000512, 2018.
2017
J. Gordon, McEwan, P., Evans, M., Puelles, J., and Sinclair, A., “Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes”, Diabetes Obes Metab, vol. 19, pp. 644-653, 2017.
2015
M. E. Nyeland, Ploug, U. J., Richards, A., L. Alvarez, G., Demuth, D., Muthutantri, A., Skovgaard, R., and Evans, M., “Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care”, Int J Clin Pract, vol. 69, pp. 281-91, 2015.
J. P. Gordon, Evans, M., Puelles, J., and McEwan, P. C., “Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy”, Diabetes Ther, vol. 6, pp. 495-507, 2015.
P. McEwan, B. Thorsted, L., Wolden, M., Jacobsen, J., and Evans, M., “Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England”, BMJ Open Diabetes Res Care, vol. 3, p. e000057, 2015.
2013
C. J. Currie, Poole, C. D., Evans, M., Peters, J. R., and Morgan, C. L., “Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes”, J Clin Endocrinol Metab, vol. 98, pp. 668-77, 2013.
2012
C. L. Morgan, Jenkins-Jones, S., Evans, M., Barnett, A. H., Poole, C. D., and Currie, C. J., “Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs”, Diabetes Obes Metab, vol. 14, pp. 424-32, 2012.
C. L. Morgan, Poole, C. D., Evans, M., Barnett, A. H., Jenkins-Jones, S., and Currie, C. J., “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes”, J Clin Endocrinol Metab, vol. 97, pp. 4605-12, 2012.
2011
S. Suissa, Azoulay, L., Dell'Aniello, S., Evans, M., Vora, J., and Pollak, M., “Long-term effects of insulin glargine on the risk of breast cancer”, Diabetologia, vol. 54, pp. 2254-62, 2011.
2010
V. Sazonov, Beetsch, J., Phatak, H., Wentworth, C., and Evans, M., “Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database”, Atherosclerosis, vol. 208, pp. 210-6, 2010.
C. J. Currie, Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., and Poole, C. D., “Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study”, Lancet, vol. 375, pp. 481-9, 2010.
[Page last reviewed 6 April 2021]